BOSTON, Nov. 6, 2023
/PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq:
NRBO), a clinical-stage biotechnology company on a quest to
transform cardiometabolic diseases, today announced the appointment
of James P. Tursi, M.D., a
pharmaceutical industry veteran, to its Board of Directors,
effective November 1, 2023. Dr. Tursi
will also serve as a member of the Board's Nominating and Corporate
Governance Committee.
"James is a proven leader, with nearly 20 years in the
pharmaceutical industry and over 30 total years of medical
experience," stated Andrew I. Koven,
Chairman of NeuroBo's Board of Directors. "Having served as both
chief medical officer and chief scientific officer of a number of
companies, over the years, James' expertise will be valuable as we
continue to advance the clinical development of our two unique and
promising cardiometabolic assets which address the large
nonalcoholic steatohepatitis (NASH) and obesity markets.
Specifically, we look forward to his counsel related to our
development of DA-1241, a novel G-Protein-Coupled Receptor 119
(GPR119) agonist, currently in a Phase 2a clinical trial for the
treatment NASH and, DA-1726, a novel oxyntomodulin (OXM) analogue
that acts as a glucagon-like peptide-1 receptor (GLP1R) and
glucagon receptor (GCGR) dual agonist, for which we expect to file
an Investigational New Drug (IND) application in the coming months,
with the planned initiation of a Phase 1a safety study during the
first half of 2024."
Dr. Tursi added, "I am honored to join the NeuroBo Board of
Directors during such a transformative stage for the Company,
especially with multiple near-term milestones on the horizon, which
could meaningfully drive shareholder value going forward. As such,
I look forward to working closely with the NeuroBo leadership team
and my fellow Directors to maximize the potential for the Company's
next generation pharmaceuticals to treat cardiometabolic
diseases."
Dr. Tursi is currently Executive Vice President – Global
Research and Development for Endo International plc, which he
joined in January 2022. Previously,
from April 2020 until January 2022, Dr. Tursi was Chief Scientific
Officer U.S. for Ferring Pharmaceuticals. From August 2018 until April
2020, Dr. Tursi served as Chief Medical Officer and
Executive Vice President, Research and Development for Antares
Pharma Inc. Earlier in his career, Dr. Tursi was the Chief Medical
Officer of Aralez Pharmaceuticals Inc., the Chief Medical Officer
and Vice President of Clinical Research and Development for
Auxilium Pharmaceuticals, Inc., and held positions of increasing
responsibility at GlaxoSmithKline plc and Procter &
Gamble Pharmaceuticals.
Dr. Tursi practiced medicine and surgery for over 10 years and
created a medical education company, I Will Pass®, which assisted
physicians in the process of board certification. He earned a
Bachelor of Science degree in chemistry and biology from
Ursinus College; a Doctor of Medicine
from Medical College of Pennsylvania
and completed his residency in Gynecology and Obstetrics at the
Johns Hopkins Hospital.
About NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals,
Inc. is a clinical-stage biotechnology company on a quest to
transform cardiometabolic diseases. The company is currently
developing DA-1241 for the treatment of Non-Alcoholic
Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM), and is
developing DA-1726 for the treatment of obesity. DA-1241 is a novel
G-Protein-Coupled Receptor 119 (GPR119) agonist, which promotes the
release of key gut peptides GLP-1, GIP, and PYY. In preclinical
studies, DA-1241 demonstrated positive effect on liver
inflammation, lipid metabolism, weight loss, and glucose
metabolism, reducing hepatic steatosis, hepatic inflammation, and
liver fibrosis, while also improving glucose control. DA-1726 is a
novel oxyntomodulin (OXM) analogue that acts as a glucagon-like
peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual
agonist. OXM is a naturally-occurring gut hormone that activates
GLP1R and GCGR, thereby decreasing food intake while increasing
energy expenditure, thus potentially resulting in superior body
weight loss compared to selective GLP1R agonists. For more
information, please visit www.neurobopharma.com.
Forward Looking Statements
Certain statements in this
release may be considered forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
including without limitation, statements about the closing of the
offering of securities. Forward-looking statements are predictions,
projections and other statements about future events that are based
on current expectations and assumptions and, as a result, are
subject to risks and uncertainties. Many factors could cause actual
future events to differ materially from the forward-looking
statements in this release, including, without limitation, those
risks associated with our ability to execute on our commercial
strategy, the timeline for regulatory submissions, regulatory steps
and potential regulatory approval of our current and future product
candidates, the ability to realize the benefits of the license
agreement with Dong-A ST Co. Ltd., including the impact on future
financial and operating results of NeuroBo; the ability to
integrate the new product candidates into NeuroBo's business in a
timely and cost-efficient manner; the cooperation of our contract
manufacturers, clinical study partners and others involved in the
development of our current and future product candidates; our
ability to initiate and complete clinical trials on a timely basis;
our ability to recruit sites and subjects for our clinical trials;
costs related to the license agreement, known and unknown,
including costs of any litigation or regulatory actions relating to
the license agreement; our ability to out-license or sell assets
related to our legacy programs; changes in applicable laws or
regulations; effects of changes to NeuroBo's stock price on the
terms of the license agreement and any future fundraising; and
other risks and uncertainties described in our filings with the
SEC. Forward-looking statements speak only as of the date when
made. NeuroBo does not assume any obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact:
Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com
View original
content:https://www.prnewswire.com/news-releases/neurobo-pharmaceuticals-strengthens-board-of-directors-with-the-appointment-of-james-p-tursi-md-301977812.html
SOURCE NeuroBo Pharmaceuticals, Inc.